NewStem is developing a technology that uses human haploid embryonic stem cells to predict cancer drug resistance.
The latest round, led by Northpond Ventures, brings the total amount raised by the
company to date to $76 million.
As Dana-Farber migrates its dozens of medical and radiation oncology protocols to the Philips platform, its focus is on digital pathology, genomics, and informatics.
The Guardian reports that England's National Health Service is to offer routine genomic medicine starting in October.
Finland-based Tieto and Swiss firm BC Platforms will jointly develop technology for integrating genomic and clinical data in the Northern European market.
Patients whose tumors had methylated MGMT promoters were more likely to survive than those that did not after combination treatment with radiotherapy and temozolomide.
The companies have launched a center that offers consulting and management specifically for genomically targeted or precision medicine trials.
An opinion piece in the Irish Times calls on Ireland to part in a European genome project.
The NCI will launch a lab network to provide researchers with centralized assays for conducting genomic and pharmacodynamic analysis for molecularly targeted drugs.
The companies are creating a new center that will offer support services to biopharmaceutical companies, CROs, and others in designing genetically informed clinical trials.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.